Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 7/20 | 0.66 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.41 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203992 | 0.85 | SCN9A (0.52) | SERPINE1SCN9APLA2G4ARXRARXRB | |
| Tiplasinin SCHEMBL29448190 | 0.79 | SERPINE1 (1.00) | SERPINE1 | |
| Tiplasinin SCHEMBL3052065 | 0.79 | SERPINE1 (1.00) | SERPINE1 | |
| SCHEMBL3866244 | 0.79 | SERPINE1 (0.68) | SERPINE1SCN9ARXRARXRBNR4A2 | |
| SCHEMBL3858076 | 0.78 | SERPINE1 (0.85) | SERPINE1SCN9ARXRARXRB | |
| SCHEMBL4757406 | 0.78 | SERPINE1 (0.69) | SERPINE1SCN9ARXRARXRBNR4A2 | |
| SCHEMBL4750090 | 0.77 | SERPINE1 (0.83) | SERPINE1RXRARXRB | |
| SCHEMBL3861341 | 0.76 | SERPINE1 (0.77) | SERPINE1SCN9ARXRARXRBNR4A2 | |
| SCHEMBL4752947 | 0.75 | SERPINE1 (1.00) | SERPINE1RXRARXRB | |
| SCHEMBL3857510 | 0.73 | SERPINE1 (1.00) | SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | claimed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | claimed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | claimed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1569901-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885SCN9A 4083/4885PLA2G4A 1457/4885 |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, PLAT, SERPINC1 | SERPINE1 1/4885SCN9A 3795/4885PLA2G4A 741/4885 |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, SERPINC1, PLAT | SERPINE1 1/4885SCN9A 3763/4885PLA2G4A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.